Brought to you by 
Forest potentially boosts GI portfolio with $1bn buy of Furiex
01 Jun 2021
Executive Summary
Just two months after Actavis PLC announced it bought Forest Laboratories Inc. for $23.9bn, Forest is making an acquisition itself, taking over publicly traded biotech Furiex Pharmaceuticals Inc. for $1bn up front in cash, or $95/share (a 20% premium).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forest potentially boosts GI portfolio with $1bn buy of Furiex
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice